← Back to patent-cliff list
PEG-Irinotecan
Tier C — Watch / tradePEG-Irinotecan
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP1
Indications (approved)：Small cell lung cancer, 三阴性乳腺癌, Brain metastases, Glioma, Glioblastoma, Solid tumour, 脑癌
Regional status
US
-
EU
-
China
Phase III
2024-10-24
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of PEG-Irinotecan?
Approved indications include: Small cell lung cancer, 三阴性乳腺癌, Brain metastases, Glioma, Glioblastoma, Solid tumour, 脑癌.
When does the PEG-Irinotecan patent expire?
No public expiry year is available for PEG-Irinotecan yet; this page updates once verified.
How do I get a quote for PEG-Irinotecan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01